A two-site assay was developed by use of the "dissociation and enhancement lanthanide fluoroimmunoassay" (DELFIA) technique for determinationof salmon calcitonin (SCT) in serum after administration to osteoporotic patients. Polyclonal antibodies were produced in rabbits immunized with SCT coupled to ovalbumin. After affinity purification, the antibodies were used both as immobilized capture antibodies and as Eu-chelate-labeled signal antibodies.A sensitiveassay with a detectionlimitof 1.1 pmol/L was achieved, and no cross-reactionwith human calcitonin was observed. The intra-and interassay CVs were <12% (n = 10) and <15% (n = 4), respectively.Analytical recovery of SCT added to serum was 91% ± 3% (mean ± SD, n = 4). SCT was measurable in all the samples from eight osteoporotic patients after subcutaneous Sd administration. We conclude that this new sensitive and specifictwosite DELFIA can reliably measure SCT in serum. Here we describe a twosite immunoreactive assay for determining SCT in blood, based on the use of europium-labeled antibodies. Use of a sandwich antigen-antibody complex provides specificity, and the fluorescence intensity of the europium chelate accounts for the sensitivity.
A two-site assay was developed by use of the "dissociation and enhancement lanthanide fluoroimmunoassay" (DELFIA) technique for determinationof salmon calcitonin (SCT) in serum after administration to osteoporotic patients. Polyclonal antibodies were produced in rabbits immunized with SCT coupled to ovalbumin. After affinity purification, the antibodies were used both as immobilized capture antibodies and as Eu-chelate-labeled signal antibodies.A sensitiveassay with a detectionlimitof 1.1 pmol/L was achieved, and no cross-reactionwith human calcitonin was observed. The intra-and interassay CVs were <12% (n = 10) and <15% (n = 4), respectively.Analytical recovery of SCT added to serum was 91% ± 3% (mean ± SD, n = 4). SCT was measurable in all the samples from eight osteoporotic patients after subcutaneous Sd administration. We conclude that this new sensitive and specifictwosite DELFIA can reliably measure SCT in serum. Our aim was to develop a sensitive immunoassay for determination of SCT in serum. The lack of sensitive and specific assays to date has meant few attempts to correlate SCT effects to its concentration in blood.
MaterIals and Methods
Clinical samples. Serum samples were collected from eight patients-ages 82 ± 4 years (mean ± SD, range 77-86), body weight 56 ± 10 kg (range 41-73), three men and five women-with x-ray-verified vertebral compression fracture due to osteoporosis. None of the subjects had previously been treated with CT of any form, and all had normal kidney and liver functions. The patients were injected subcutaneously in the abdomen with SCT (100 lUlL, Miacalcic#{174}; Sandoz, Basel, Switzerland), 50 IU for subjects <60 kg and 100 IU for those >60 kg. For each subject 10 mL of blood was drawn from a cubital vein at various times before and after The SCT antibodies in the dialyzed IgG product were extracted by SCT coupled to Sepharose in a tube and rotated for 2 h at room temperature. The unbound IgG was washed away with PBS in a 1 x 15 cm Econo-column (Bio-Rad, Richmond, CA), and the antibodies directed against SCT were eluted with 1 molJL acetic acid. After dialysis against PBS, the antibodies were divided into two portions, frozen, and lyophilized.
One portion of the freeze-dried product was dissolved in 0.5 mL of distified water, and the amount of SCT antibodies was determined by using a protein assay reagent (Bio-Rad). One portion was used as capture antibodies, and the other was labeled with europium chelate for use as signal antibodies.
The possibility of using the same batch of affinity-purified polyclonal antibodies for both sites in a two-site antibody-sandwich assay has been described earlier (7). Testing the two affinity-purified antibodies 309# and 246# in four possible combination "pairs" showed that the most sensifive assay was achieved with 309# as both capture and signal antibody.
We used a DELFIA Eu-labeling kit (Wailac Oy, Turku, Finland) to label the purified SCT antibody. The freeze-dried antibodies were dissolved in labeling buffer (50 mmoIfL NaHCO3, pH 8. 
Results

Methodological
aspects. In this SCT DELFIA, the fluorescence counts of serially diluted SCT demonstrated linearity, and the dilutions of serum samples as well as of SCT added to serum showed parallelism to the SCT calibration curve (Fig. 1) . The detection limit, based on 2 SD (n = 6) above the blank fluorescence, was 1.1 pmol/L (3.9 ng/L). Given that only 150 jzL of standard or 
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sample was added to each well, amounts as small as 0.6 pg of SCT can be detected in a well. The intraassay CVs were 11% (n = 10) and the interassay CVs for 5, 15 and 25 pmol/L were 15%, 5%, and 8% (n = 4), respectively. There was no cross-reaction with human CT. The binding capacity of the antibodies for SCT is >2 nmol/L with --150 ng of antibodies coated per well. Analytical recovery of 5, 10,15, and 20 pmol/L SCT added to serum was 91% ± 3% (mean ± SD, n = 4). Recovery of 50 pmoIfL SCT added to serum at 1:2, 1:4, 1:8, and 1:16 dilutions was 94% ± 9% (n = 4). Pharmacokinetics of SCT in osteoporotic patients. The mean serum concentration of SCT in eight osteoporotic patients receiving an average dose of 1.20 ± 0.29 lU/kg of body wt. is shown in Fig. 2A ; the individual values for each subject are shown in Fig. 2B . SCT reached its highest concentration in all subjects by 30-60 miii after injection; after 120 miii, it had decreased by 20-50%. The higher the peak concentrations, the more they decreased. By 8 h SCT was undetectable in most subjects. Because of the differences in the doses given (lU/kg body wt.) and the individual variations in the absorption and metabolism, the peak concentrations 
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Cs the dosage and the peak value was well as the area below each curve demonstrated a great individual variation in drug absorption and metabolism (Fig. 3) .
DIscussion
Treatment of postmenopausal osteoporosis with subcutaneously or intranasally administered SCT has become widely used in recent years, now that the hormone has been registered for this indication in increasing number of countries. The treatment effectively inhibits the bone resorption and decreases the rate of bone loss in the majority of patients. However, the effect is dosedependent; moreover, SCT has little therapeutic effect in some patients and includes side effects such as flushing and gastrointestinal disturbance in many patients. The bioavailability and pharmacokinetics of SCT vary considerably between patients and depend on the mode of administration (8, 9). We believe that a sensitive two-site assay, such as was presented here, can be a valuable tool for pharmacokinetic studies in the near future.
SCT was first determined by immunoassay in fish (10, 11); a sensitive assay was not necessary because of the high SCT concentrations. Later, immunoassays were used to study the pharmacokunetics of SCT in humans who were using the drug for treatment of skeletal diseases (12, 13) . When SCT is administered subcutaneously in relatively low doses, as in our study, a sensitive assay is needed. The DELFIA method could measure SCT in every sample from subjects administered 50 or 100 IU of SCT. The lower dose in patients weighing <60 kg was chosen to avoid side effects (e.g., nausea and vomiting), which are not uncommon and sometimes pronounced.
A two-site assay has a high specificity for the antigen to be measured, because of the requirement that two parts of the antigen have to be recognized by the antibodies. This two-site assay with a lanthanide as the signal substance obtained 10 times greater sensitivity than an earlier two-site IRMA (14) and has the advantage of using nonradioactive markers with long stability. In our hands the europium-labeled SCT antibodies were stable for >1 year. H.R was a recipient of the fellowship from the Wenner-Gren
